Patents by Inventor Wey Jia Fong
Wey Jia Fong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132595Abstract: The invention relates to antigen-binding molecules that specifically bind to MHC Class I DLA-12 antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine MHC Class I DLA-12 antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.Type: ApplicationFiled: January 28, 2022Publication date: April 25, 2024Applicant: Agency for Science, Technology and ResearchInventors: Chui Ping Angela CHIN, Boon Hwa Andre CHOO, Wey Jia FONG, Mei Yee Vanessa DING
-
Publication number: 20240018221Abstract: The invention relates generally to antigen-binding molecules that specifically bind to Myosin Heavy Chain 9 (MYH9) and uses thereof for the treatment of specific cancers, such as mast cell tumors. In one embodiment, the MYH9 is canine MYH9 and the antigen-binding molecule is an antibody. In another embodiment, the antigen-binding molecule is conjugated to a toxin, for the treatment of canine mast cell tumors.Type: ApplicationFiled: October 26, 2021Publication date: January 18, 2024Applicant: Agency for Science, Technology and ResearchInventors: Wey Jia FONG, Boon Hwa CHOO, Mei Yee Vanessa DING, Chui Ping CHIN
-
Patent number: 11697681Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYSITSGYSWH; a VHCDR2 having the amino acid sequence YIHYSGSTKYNPSLKS and a VHCDR3 having the amino acid sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLYSNDQKNYLA, a VLCDR2 having the amino acid sequence WASIRES, and a VLCDR3 having the amino acid sequence QQYYIYPLT.Type: GrantFiled: April 14, 2020Date of Patent: July 11, 2023Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simeon Cua, Andre Boon Hwa Choo, Heng Liang Tan, Wey Jia Fong, Vanessa Mei Yee Ding, Leonard Wen Yan Leong
-
Patent number: 11306153Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, therapeutic use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.Type: GrantFiled: May 22, 2017Date of Patent: April 19, 2022Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Mei Yee Vanessa Ding, Boon Hwa Andre Choo, Wey Jia Fong
-
Publication number: 20200399353Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYSITSGYSWH; a VHCDR2 having the amino acid sequence YIHYSGSTKYNPSLKS and a VHCDR3 having the amino acid sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLYSNDQKNYLA, a VLCDR2 having the amino acid sequence WASIRES, and a VLCDR3 having the amino acid sequence QQYYIYPLT.Type: ApplicationFiled: April 14, 2020Publication date: December 24, 2020Inventors: Simeon CUA, Andre Boon Hwa CHOO, Heng Liang TAN, Wey Jia FONG, Vanessa Mei Yee DING, Leonard Wen Yan LEONG
-
Publication number: 20200317812Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to a glycan on the AXL receptor tyrosine kinase. The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or cytotoxin, and wherein said antigen-binding proteins, or antigen-binding fragment is internalised into a cell upon binding to AXL receptor tyrosine kinase. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, therapeutic use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.Type: ApplicationFiled: May 22, 2017Publication date: October 8, 2020Inventors: Mei Yee Vanessa DING, Boon Hwa Andre CHOO, Wey Jia FONG
-
Patent number: 10654921Abstract: The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence GYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.Type: GrantFiled: July 26, 2017Date of Patent: May 19, 2020Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simeon Cua, Andre Boon Hwa Choo, Heng Liang Tan, Wey Jia Fong, Vanessa Mei Yee Ding, Leonard Wen Yan Leong
-
Publication number: 20190177405Abstract: The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence GYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.Type: ApplicationFiled: July 26, 2017Publication date: June 13, 2019Inventors: Simeon CUA, Andre Boon Hwa CHOO, Heng Liang TAN, Wey Jia FONG, Vanessa Mei Yee DING, Leonard Wen Yan LEONG
-
Patent number: 8906678Abstract: The disclosure relates to methods of binding and identifying undifferentiated pluripotent stem cells and particularly, although not exclusively, to use of binding moieties which bind to PHB on the surface of undifferentiated pluripotent stem cells, such as PHB-binding peptides, and to methods for depleting undifferentiated stem cells from a sample.Type: GrantFiled: March 10, 2011Date of Patent: December 9, 2014Assignee: Agency for Science, Technology and ResearchInventors: Boon Hwa Andre Choo, Wey Jia Fong
-
Publication number: 20130115623Abstract: The disclosure relates to methods of binding and identifying undifferentiated pluripotent stem cells and particularly, although not exclusively, to use of binding moieties which bind to PHB on the surface of undifferentiated pluripotent stem cells, such as PHB-binding peptides, and to methods for depleting undifferentiated stem cells from a sample.Type: ApplicationFiled: March 10, 2011Publication date: May 9, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Boon Hwa Andre Choo, Wey Jia Fong